Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL 61656, USA.
Stem Cells Dev. 2012 Jul 1;21(10):1779-93. doi: 10.1089/scd.2011.0424. Epub 2011 Nov 21.
Previously, we have shown that human umbilical cord blood stem cell (hUCBSC) treatment downregulate cyclin D1 in glioma cells. To study the cell cycle progression and investigate the upstream molecules regulating cyclin D1 expression, we analyzed the involvement of extracellular signal-regulated kinase (ERK) and its functionality after treatment with hUCBSC. We observed downregulation of pERK after hUCBSC treatment at both transcriptional and translational levels. Increased translocation of ERK from cytoplasm to the nucleus was observed in glioma cells, whereas hUCBSC cocultures with glioma cells showed suppressed nuclear translocation. This finding suggests that hUCBSC regulates ERK by suppressing its phosphorylation at phospho-Thr(202)/Tyr(204) retarding pERK nuclear translocation. ERK promoter analysis has shown c-Myc binding sites, indicative of possible transcriptional interactions that regulate cyclin D1 and ERK expression levels. Treatment of U251 and 5310 glioma cells with U0126, a MEK/ERK inhibitor receded pERK and c-Myc levels. In another experiment, U251 and 5310 cells treated with 10074-G5, c-Myc/Max inhibitor displayed reduction in pERK and c-Myc levels suggestive of a positive feedback loop between ERK/c-Myc/Max molecules. In the present study, we show that glioma cells exhibit abundant c-Myc expression and increased c-Myc/Max activity. In contrast, the glioma cells cocultured with hUCBSC demonstrated high Mad1 expression that competitively binds to Max to repress the c-Myc/Max mediated gene transcription. Our studies thus elucidate the potential role of hUCBSC in controlling glioma cell cycle progression and invasion by limiting Max binding to c-Myc, thus regulating the expression of glioma cell cycle and invasion associated molecules such as ERK, integrins via increased levels of Mad1 expression.
先前,我们已经表明,人脐带血干细胞(hUCBSC)治疗可下调神经胶质瘤细胞中的细胞周期蛋白 D1。为了研究细胞周期进程并研究调节细胞周期蛋白 D1表达的上游分子,我们分析了细胞外信号调节激酶(ERK)及其在 hUCBSC 处理后的功能。我们观察到 hUCBSC 处理后,pERK 在转录和翻译水平均下调。在神经胶质瘤细胞中观察到 ERK 从细胞质向细胞核易位增加,而 hUCBSC 与神经胶质瘤细胞共培养则显示核易位受到抑制。这一发现表明,hUCBSC 通过抑制磷酸化 ERK 在磷酸化 Thr(202)/Tyr(204)处的磷酸化来调节 ERK,从而阻止 pERK 核易位。ERK 启动子分析显示 c-Myc 结合位点,提示可能存在调节细胞周期蛋白 D1 和 ERK 表达水平的转录相互作用。用 MEK/ERK 抑制剂 U0126 处理 U251 和 5310 神经胶质瘤细胞,可使 pERK 和 c-Myc 水平降低。在另一个实验中,用 c-Myc/Max 抑制剂 10074-G5 处理 U251 和 5310 细胞,显示 pERK 和 c-Myc 水平降低,提示 ERK/c-Myc/Max 分子之间存在正反馈环。在本研究中,我们表明神经胶质瘤细胞表现出丰富的 c-Myc 表达和增加的 c-Myc/Max 活性。相比之下,与 hUCBSC 共培养的神经胶质瘤细胞显示出高水平的 Mad1 表达,Mad1 竞争性结合 Max 以抑制 c-Myc/Max 介导的基因转录。我们的研究因此阐明了 hUCBSC 通过限制 Max 与 c-Myc 的结合来控制神经胶质瘤细胞周期进程和侵袭的潜在作用,从而通过增加 Mad1 表达来调节神经胶质瘤细胞周期和侵袭相关分子(如 ERK、整合素)的表达。